{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vaccine+Safety&page=2",
    "query": {
      "condition": "Vaccine Safety",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 1829,
    "total_pages": 183,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vaccine+Safety&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vaccine+Safety&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T07:58:04.748Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04078022",
      "title": "Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Shigella"
      ],
      "interventions": [
        {
          "name": "SF2a-TT15 Shigella Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "S. flexneri 2a strain 2457T Challenge Agent",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 58,
      "start_date": "2020-03-02",
      "completion_date": "2024-01-25",
      "has_results": true,
      "last_update_posted_date": "2024-05-20",
      "last_synced_at": "2026-09-30T07:58:04.748Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04078022"
    },
    {
      "nct_id": "NCT07051031",
      "title": "COVID-19 Reactogenicity",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Nuvaxovid (NVX-CoV2705)",
          "type": "DRUG"
        },
        {
          "name": "mNEXSPIKE mRNA-1283",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marcel Curlin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2025-10-01",
      "completion_date": "2026-06-14",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-09-30T07:58:04.748Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07051031"
    },
    {
      "nct_id": "NCT05242965",
      "title": "A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Non-Small Cell Carcinoma",
        "Stage IV Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2023-03-24",
      "completion_date": "2032-11-21",
      "has_results": true,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-09-30T07:58:04.748Z",
      "location_count": 2,
      "location_summary": "Omaha, Nebraska • Seattle, Washington",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05242965"
    },
    {
      "nct_id": "NCT04886154",
      "title": "A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Infections, Meningococcal"
      ],
      "interventions": [
        {
          "name": "MenABCWY-2Gen low dose vaccine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "MenABCWY-2Gen high dose vaccine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "MenB vaccine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "MenACWY vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "10 Years to 50 Years"
      },
      "enrollment_count": 1440,
      "start_date": "2021-06-14",
      "completion_date": "2024-02-02",
      "has_results": true,
      "last_update_posted_date": "2025-05-31",
      "last_synced_at": "2026-09-30T07:58:04.748Z",
      "location_count": 12,
      "location_summary": "Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Longmont",
          "state": "Colorado"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04886154"
    },
    {
      "nct_id": "NCT03186781",
      "title": "Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "VRC-FLUNPF081-00-VP (HA-F A/Sing)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VRC-FLUDNA082-00-VP (DNA A/Sing)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2017-10-25",
      "completion_date": "2019-09-03",
      "has_results": true,
      "last_update_posted_date": "2021-06-16",
      "last_synced_at": "2026-09-30T07:58:04.748Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03186781"
    },
    {
      "nct_id": "NCT04534205",
      "title": "A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Unresectable Head and Neck Squamous Cell Carcinoma",
        "Metastatic Head and Neck Cancer",
        "Recurrent Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "BNT113",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 358,
      "start_date": "2021-01-07",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-09-30T07:58:04.748Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04534205"
    },
    {
      "nct_id": "NCT01889719",
      "title": "A Phase I Study to Evaluate the Safety and Immunogenicity of Heterologous Boost Immunizations With MVA-CMDR",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "MVA-CMDR",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Rockefeller University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "62 Years",
        "sex": "ALL",
        "summary": "18 Years to 62 Years"
      },
      "enrollment_count": 14,
      "start_date": "2014-01",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2016-02-17",
      "last_synced_at": "2026-09-30T07:58:04.748Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01889719"
    },
    {
      "nct_id": "NCT00943631",
      "title": "Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Inactivated H1N1 Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 406,
      "start_date": "2009-08",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2012-10-31",
      "last_synced_at": "2026-09-30T07:58:04.748Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Durham, North Carolina • Nashville, Tennessee",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00943631"
    },
    {
      "nct_id": "NCT06838000",
      "title": "Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Infections"
      ],
      "interventions": [
        {
          "name": "PCV21",
          "type": "BIOLOGICAL"
        },
        {
          "name": "20vPCV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Months to 17 Years"
      },
      "enrollment_count": 1268,
      "start_date": "2025-02-28",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-06",
      "last_synced_at": "2026-09-30T07:58:04.748Z",
      "location_count": 17,
      "location_summary": "Paramount, California • Doral, Florida • Hialeah, Florida + 13 more",
      "locations": [
        {
          "city": "Paramount",
          "state": "California"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06838000"
    },
    {
      "nct_id": "NCT00807781",
      "title": "Mammaglobin-A DNA Vaccine for Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Mammaglobin-A DNA vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2009-10",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-01-05",
      "last_synced_at": "2026-09-30T07:58:04.748Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00807781"
    }
  ]
}